Forget Kalshi Bets: This Under-the-Radar Sports Data Stock Could Actually Mint Millionaires

Genius Sports (NYSE: GENI) is highlighted as a picks-and-shovels beneficiary of the rise of prediction markets and sports wagering, with shares down more than 60% year to date and trading just under $4.50. The article cites a potential post-merger EBITDA increase from $190 million to as much as $320 million and operating margin expansion from 23% to 30% after the $900 million Legend acquisition plus $300 million earnout. Sell-side forecasts call for EPS of $0.28 in 2027 and $0.60 in 2028, suggesting a possible rebound if growth and integration play out.

Analysis

The key read-through is that GENI is less a “betting stock” and more a toll collector on market structure expansion. If prediction markets keep gaining share, the scarce asset is verified real-time sports data and integrity tooling, not retail trading flow; that makes GENI more levered to category adoption than to winner-take-all platform economics. The market is likely still discounting it as a low-quality sports-tech name, which creates a gap between narrative and asset-light operating leverage once fixed costs are absorbed.

The upcoming merger matters more for multiple expansion than for headline EBITDA. If management can credibly show post-close margin expansion and cross-sell into adtech, the stock can re-rate from “ex-growth data vendor” to “scaled, recurring infrastructure platform,” especially because incremental revenue should fall through hard after profitability inflects. The bigger second-order effect is competitive: DKNG and FLUT can own demand, but they remain exposed to product and regulatory friction; GENI benefits regardless of which front-end wins, as long as market-making, live data, and settlement volumes rise.

The main risk is timing mismatch: the market may have to wait quarters for the merger synergies to show up while sentiment remains anchored to past execution misses. Another risk is that prediction markets stay niche or face regulatory constraints, in which case GENI’s optionality is overstated and the current bounce fails. Near term, the stock is driven more by guidance credibility and integration milestones than by end-market excitement; if those disappoint, the move can retrace quickly even if the secular thesis remains intact.

Consensus appears to be underappreciating how much of GENI’s value can come from being infrastructure to both regulated sportsbooks and prediction markets, rather than trying to predict which interface dominates. The contrarian point is that the stock may not need the category to explode to work; even modest volume growth plus operating leverage can produce outsized EPS expansion from a depressed base. That said, if the market starts pricing 2027–2028 estimates too aggressively before the merger is digested, upside becomes more fragile and a pullback becomes a better entry.

Key Decisions for Investors

• Long GENI on a 3-6 month horizon into merger integration milestones; risk/reward is attractive if execution confirms the EBITDA bridge, but size modestly because the thesis depends on credibility as much as growth.
• Use a staged entry in GENI: buy 1/3 now, 1/3 after the next quarterly print, 1/3 on post-close synergy evidence; this lowers the risk of catching a dead-cat bounce in a name with still-high execution dispersion.
• Pair long GENI / short DKNG for a relative-value bet on picks-and-shovels exposure versus front-end sportsbook operating leverage; works if regulation broadens market volumes but unit economics stay pressured at the operator level.
• For higher convexity, consider GENI call spreads 6-12 months out rather than outright equity; the catalyst is a rerating on EBITDA credibility, and the defined risk helps if the integration timetable slips.
• Trim or avoid adding if GENI rallies materially ahead of visible post-merger margin realization; at that point the stock likely shifts from under-owned to story-owned, reducing the asymmetry.